Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Published Time:
2021-03-08 18:01
Source:
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
Founded in 2010, Jiangsu Vcare specializes in end-to-end R&D, services, and innovation across the chemical drug industry chain. Headquartered in Nanjing Biotech and Pharmaceutical Valley, the company employs 280 staff, with over 50% of its R&D team holding master’s or doctoral degrees. It operates a 21,000 sqm high-end drug R&D center equipped with fully functional synthesis, analysis, formulation, cell, and enzyme activity testing laboratories. Its experienced teams in medicinal chemistry, CMC, and clinical development operate under internationally advanced management models, providing comprehensive R&D capabilities spanning "Chemistry + Pharmacy + Medicine".
Focusing on unmet clinical needs in cardiovascular, oncology, and endocrine diseases, Jiangsu Vcare has developed multiple competitive innovative products through independent R&D and collaborative innovation. Its flagship drug Vicagrel—which has completed Phase II trials—was recognized as "one of the most commercially promising projects in its field." The second-generation NTRK inhibitor has entered Phase I, while a highly selective JAK1 inhibitor is nearing IND submission. The pipeline includes multiple first-in-class (FIC) and best-in-class (BIC) preclinical candidates.
In recent years, Jiangsu Vcare has steadily advanced its innovative drug programs while achieving rapid growth in contract services. With investor support, the company aims to accelerate clinical research and deliver more high-quality therapeutics to global patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely appreciate our investors’ recognition of Jiangsu Vcare and their trust in our team. We are in an exhilarating era of innovation, where developing novel drugs to address clinical needs remains our unwavering mission. Simultaneously, in this service-driven economy, we are committed to providing one-stop, full-process drug R&D services that create value for clients. Moving forward, we will continue to prioritize independent innovation and open collaboration to unlock limitless potential."
Next Page
Next Page
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn